The standard of care for managing patients with type 2 diabetes and CKD -- in addition to a healthy lifestyle -- has always ...

Prompt treatment with a drug combo can effectively manage chronic kidney disease in people with type 2 diabetes, a new ...

Adults with chronic kidney disease and type 2 diabetes had slower kidney function decline with a combination of the and ...

New data from the CONFIDENCE trial demonstrates that combination therapy with finerenone and empagliflozin leads to ...

Simultaneous treatment start with finerenone and SGLT-2-inhibitor demonstrated positive data in patients with CKD associated with type 2 diabetes: Berlin Saturday, June 7, 2025, 1 ...

Adding an SGLT2 inhibitor to finerenone in CKD and type 2 diabetes yields “remarkable” albuminuria reductions that may, if ...

The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

Mineralys Therapeutics, Inc.'s lorundrostat shows promise for treating aldosterone-driven hypertension with FDA approval by ...

The VALIANT Phase 3 trial shows that pegcetacoplan significantly reduces proteinuria and stabilises kidney function in ...

The AHA’s PREVENT equations, compared with pooled cohort equations, can better predict 10-year ASCVD risk among US adults.

Objective: We assessed plasma adiponectin and its correlation with carotid intima-media-thickness (CIMT), as a marker of atherosclerosis, and urine albumin/creatinine ratio (ACR) in patients with ...